{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once-daily&page=2", "query": { "intervention": "Placebo once-daily", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 5485, "total_pages": 549, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once-daily&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once-daily&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T06:26:37.589Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00453999", "title": "Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Peramivir 200 mg", "type": "DRUG" }, { "name": "Peramivir 400 mg", "type": "DRUG" }, { "name": "Oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2007-07", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2015-02-12", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 41, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453999" }, { "nct_id": "NCT00548587", "title": "Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "E5555", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "45 Years to 80 Years" }, "enrollment_count": 600, "start_date": "2007-10", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 1, "location_summary": "Beloit, Wisconsin", "locations": [ { "city": "Beloit", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548587" }, { "nct_id": "NCT02275052", "title": "A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC/VI DPI", "type": "DRUG" }, { "name": "Placebo DPI", "type": "DRUG" }, { "name": "Albuterol/salbutamol MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 198, "start_date": "2015-01-23", "completion_date": "2016-06-02", "has_results": true, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 10, "location_summary": "Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Medford", "state": "Oregon" }, { "city": "Anderson", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02275052" }, { "nct_id": "NCT00842816", "title": "Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "ST101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sonexa Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 210, "start_date": "2009-02", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 27, "location_summary": "Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00842816" }, { "nct_id": "NCT05568706", "title": "A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "RSV Infection" ], "interventions": [ { "name": "EDP-938", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enanta Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2022-11-29", "completion_date": "2025-06-23", "has_results": true, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 31, "location_summary": "Tempe, Arizona • Fresno, California • Lomita, California + 26 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568706" }, { "nct_id": "NCT04519658", "title": "A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resistant Hypertension" ], "interventions": [ { "name": "CIN-107", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CinCor Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2020-10-12", "completion_date": "2022-06-14", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04519658" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT04472598", "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Placebo for Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2020-09-29", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 35, "location_summary": "Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04472598" }, { "nct_id": "NCT01517698", "title": "A Study of RO4917523 in Patients With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO4917523 0.5 mg", "type": "DRUG" }, { "name": "RO4917523 1.5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "14 Years to 50 Years" }, "enrollment_count": 185, "start_date": "2012-05", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Long Beach, California • Sacramento, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517698" }, { "nct_id": "NCT01712321", "title": "Study of Vilazodone to Treat Social Anxiety Disorder", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medical Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2012-10", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-01-20", "last_synced_at": "2026-10-01T06:26:37.589Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712321" } ] }